Cargando…

miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development

BACKGROUND: Metastasis is one of the main reasons for treatment failure in endometrial cancer. Notably, high mobility group AT-hook 2 (HMGA2) has been recognized as a driving factor of tumour metastasis. microRNAs (miRNAs) are powerful posttranscriptional regulators of HMGA2. METHODS: The binding si...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jian, Li, Da, Kong, Fan-Fei, Yang, Di, Yang, Hui, Ma, Xiao-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796297/
https://www.ncbi.nlm.nih.gov/pubmed/29391048
http://dx.doi.org/10.1186/s13046-018-0686-6
_version_ 1783297479021690880
author Ma, Jian
Li, Da
Kong, Fan-Fei
Yang, Di
Yang, Hui
Ma, Xiao-Xin
author_facet Ma, Jian
Li, Da
Kong, Fan-Fei
Yang, Di
Yang, Hui
Ma, Xiao-Xin
author_sort Ma, Jian
collection PubMed
description BACKGROUND: Metastasis is one of the main reasons for treatment failure in endometrial cancer. Notably, high mobility group AT-hook 2 (HMGA2) has been recognized as a driving factor of tumour metastasis. microRNAs (miRNAs) are powerful posttranscriptional regulators of HMGA2. METHODS: The binding sites of miR-302a-5p and miR-367-3p on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. The expression levels of miR-302a-5p and miR-367-3p were detected using quantitative real-time PCR and in situ hybridization. Western blotting and immunohistochemistry were used to detect the levels of HMGA2 and epithelial-mesenchymal transition pathway-related proteins. Co-immunoprecipitation was used to detect protein interactions. The roles of miR-302a-5p and miR-367-3p in the regulation of HMGA2 during the progression of endometrial cancer were investigated using both in vitro and in vivo assays. RESULTS: In the present study, high HMGA2 expression was correlated with poor clinical outcomes in endometrial cancer. The binding sites of miRNAs on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. In the endometrial cancer cell lines Ishikawa and HEC-1A, the overexpression of miR-302a-5p/367-3p significantly inhibited the expression of HMGA2 mRNA. In endometrial cancer tissues, we showed that miR-302a-5p and miR-367-3p were significantly downregulated and thus inversely correlated with HMGA2. The miR-302a-5p and miR-367-3p expression levels were closely correlated with FIGO stage and lymph node metastasis. High expression of miR-302a-5p/367-3p was correlated with high survival rates in endometrial cancer. In addition, miR-302a-5p/367-3p suppressed the malignant behaviour of endometrial carcinoma cells via the inhibition of HMGA2 expression. CONCLUSION: Our findings indicate that miR-302a-5p/367-3p-mediated expression of HMGA2 regulates the malignant behaviour of endometrial carcinoma cells, which suggests that the miR-302a-5p/367-3p-HMGA2 axis may be a predictive biomarker of endometrial cancer metastasis and patient survival and a potential therapeutic target in metastatic endometrial cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0686-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5796297
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57962972018-02-12 miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development Ma, Jian Li, Da Kong, Fan-Fei Yang, Di Yang, Hui Ma, Xiao-Xin J Exp Clin Cancer Res Research BACKGROUND: Metastasis is one of the main reasons for treatment failure in endometrial cancer. Notably, high mobility group AT-hook 2 (HMGA2) has been recognized as a driving factor of tumour metastasis. microRNAs (miRNAs) are powerful posttranscriptional regulators of HMGA2. METHODS: The binding sites of miR-302a-5p and miR-367-3p on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. The expression levels of miR-302a-5p and miR-367-3p were detected using quantitative real-time PCR and in situ hybridization. Western blotting and immunohistochemistry were used to detect the levels of HMGA2 and epithelial-mesenchymal transition pathway-related proteins. Co-immunoprecipitation was used to detect protein interactions. The roles of miR-302a-5p and miR-367-3p in the regulation of HMGA2 during the progression of endometrial cancer were investigated using both in vitro and in vivo assays. RESULTS: In the present study, high HMGA2 expression was correlated with poor clinical outcomes in endometrial cancer. The binding sites of miRNAs on HMGA2 mRNA were identified using bioinformatics prediction software and were validated via luciferase assay. In the endometrial cancer cell lines Ishikawa and HEC-1A, the overexpression of miR-302a-5p/367-3p significantly inhibited the expression of HMGA2 mRNA. In endometrial cancer tissues, we showed that miR-302a-5p and miR-367-3p were significantly downregulated and thus inversely correlated with HMGA2. The miR-302a-5p and miR-367-3p expression levels were closely correlated with FIGO stage and lymph node metastasis. High expression of miR-302a-5p/367-3p was correlated with high survival rates in endometrial cancer. In addition, miR-302a-5p/367-3p suppressed the malignant behaviour of endometrial carcinoma cells via the inhibition of HMGA2 expression. CONCLUSION: Our findings indicate that miR-302a-5p/367-3p-mediated expression of HMGA2 regulates the malignant behaviour of endometrial carcinoma cells, which suggests that the miR-302a-5p/367-3p-HMGA2 axis may be a predictive biomarker of endometrial cancer metastasis and patient survival and a potential therapeutic target in metastatic endometrial cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0686-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-01 /pmc/articles/PMC5796297/ /pubmed/29391048 http://dx.doi.org/10.1186/s13046-018-0686-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ma, Jian
Li, Da
Kong, Fan-Fei
Yang, Di
Yang, Hui
Ma, Xiao-Xin
miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title_full miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title_fullStr miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title_full_unstemmed miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title_short miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development
title_sort mir-302a-5p/367-3p-hmga2 axis regulates malignant processes during endometrial cancer development
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796297/
https://www.ncbi.nlm.nih.gov/pubmed/29391048
http://dx.doi.org/10.1186/s13046-018-0686-6
work_keys_str_mv AT majian mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment
AT lida mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment
AT kongfanfei mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment
AT yangdi mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment
AT yanghui mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment
AT maxiaoxin mir302a5p3673phmga2axisregulatesmalignantprocessesduringendometrialcancerdevelopment